Literature DB >> 31153141

Dynamic contrast-enhanced magnetic resonance imaging perfusion characteristics in meningiomas treated with resection and adjuvant radiosurgery.

Swathi Chidambaram1, Susan C Pannullo1, Michelle Roytman2, David J Pisapia3, Benjamin Liechty3, Rajiv S Magge4, Rohan Ramakrishna1, Philip E Stieg1, Theodore H Schwartz1, Jana Ivanidze2.   

Abstract

OBJECTIVEThere is a need for advanced imaging biomarkers to improve radiation treatment planning and response assessment. T1-weighted dynamic contrast-enhanced perfusion MRI (DCE MRI) allows quantitative assessment of tissue perfusion and blood-brain barrier dysfunction and has entered clinical practice in the management of primary and secondary brain neoplasms. The authors sought to retrospectively investigate DCE MRI parameters in meningiomas treated with resection and adjuvant radiation therapy using volumetric segmentation.METHODSA retrospective review of more than 300 patients with meningiomas resected between January 2015 and December 2018 identified 14 eligible patients with 18 meningiomas who underwent resection and adjuvant radiotherapy. Patients were excluded if they did not undergo adjuvant radiation therapy or DCE MRI. Demographic and clinical characteristics were obtained and compared to DCE perfusion metrics, including mean plasma volume (vp), extracellular volume (ve), volume transfer constant (Ktrans), rate constant (kep), and wash-in rate of contrast into the tissue, which were derived from volumetric analysis of the enhancing volumes of interest.RESULTSThe mean patient age was 64 years (range 49-86 years), and 50% of patients (7/14) were female. The average tumor volume was 8.07 cm3 (range 0.21-27.89 cm3). The median Ki-67 in the cohort was 15%. When stratified by median Ki-67, patients with Ki-67 greater than 15% had lower median vp (0.02 vs 0.10, p = 0.002), and lower median wash-in rate (1.27 vs 4.08 sec-1, p = 0.04) than patients with Ki-67 of 15% or below. Logistic regression analysis demonstrated a statistically significant, moderate positive correlation between ve and time to progression (r = 0.49, p < 0.05). Furthermore, there was a moderate positive correlation between Ktrans and time to progression, which approached, but did not reach, statistical significance (r = 0.48, p = 0.05).CONCLUSIONSThis study demonstrates a potential role for DCE MRI in the preoperative characterization and stratification of meningiomas, laying the foundation for future prospective studies incorporating DCE as a biomarker in meningioma diagnosis and treatment planning.

Entities:  

Keywords:  BED = biologically effective dose; DCE = dynamic contrast-enhanced; DCE MRI; Ktrans = volume transfer constant; SRS = stereotactic radiosurgery; TTP = time to progression; kep = rate constant; meningioma; perfusion; rCBV = relative cerebral blood volume; radiosurgery; ve = extracellular volume; vp = mean plasma volume

Year:  2019        PMID: 31153141     DOI: 10.3171/2019.3.FOCUS1954

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  3 in total

1.  PET/MR Imaging of Somatostatin Receptor Expression and Tumor Vascularity in Meningioma: Implications for Pathophysiology and Tumor Outcomes.

Authors:  Michelle Roytman; Sean Kim; Shannon Glynn; Charlene Thomas; Eaton Lin; Whitney Feltus; Rajiv S Magge; Benjamin Liechty; Theodore H Schwartz; Rohan Ramakrishna; Nicolas A Karakatsanis; Susan C Pannullo; Joseph R Osborne; Jonathan P S Knisely; Jana Ivanidze
Journal:  Front Oncol       Date:  2022-01-28       Impact factor: 6.244

2.  Apparent Diffusion Coefficient Values and Dynamic Contrast-Enhanced Magnetic Resonance Perfusion are Potential Predictors for Grading Meningiomas.

Authors:  Sri Andreani Utomo; Abdul Hafid Bajamal; Yuyun Yueniwati; Irfan Deny Sanjaya; Dyah Fauziah
Journal:  Int J Med Sci       Date:  2022-07-18       Impact factor: 3.642

3.  Outcomes following upfront radiation versus monitoring in atypical meningiomas: 16-year experience at a tertiary medical center.

Authors:  Peter C Pan; David J Pisapia; Rohan Ramakrishna; Theodore H Schwartz; Susan C Pannullo; Jonathan P S Knisely; Gloria C Chiang; Jana Ivanidze; Philip E Stieg; Benjamin Liechty; Andrew Brandmaier; Howard A Fine; Rajiv S Magge
Journal:  Neurooncol Adv       Date:  2021-06-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.